AmTrust Financial Servs Stock (OTC: AFSIB)

Latest news for AmTrust Financial Servs (OTC:AFSIB) Stock

AmTrust Financial Services Inc is a multinational company that underwrites and provides property and casualty insurance products. The company specializes in coverage for small to mid-sized businesses, with a philosophical focus on niche diversity and low-hazard risk. AmTrust's business model strives to achieve its profit goals through geographic and product diversification. The company reports three business segments: Small Commercial Business, Specialty Risk and Extended Warranty, and Specialty Program. The vast majority of revenues is derived from its Small Commercial Business risk.

AMTRUST FINCL D/S PFD B by AmTrust Financial Services, Inc.

AmTrust Financial Services Inc

Biotech

General

BIVI

BioVie Announces Approval From U.S. Army Medical Research and Development Command, Office of Human Research Oversight For Its Plan To Evaluate Bezisterim In Long Covid, Co. Receives $13.1M In Funding

Cantor Fitzgerald analyst Eric Schmidt reiterates bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) with a Neutral.

News

Reiteration

Analyst Ratings

BLUE

Cantor Fitzgerald Reiterates Neutral on bluebird bio

Homebuyers are increasingly focused on <a href="https://www.benzinga.com/real-estate/24/06/39433664/top-ten-list-of-cities-where-americans-are-moving-shows-if-you-build-it-affordably-they-will-come">specific pockets of the Midwest</a> and Northeast in a housing market characterized by high prices and rising mortgage rates. The areas offer a balance of affordability and desirability, according to a recent study by Realtor.com.
Don't Miss:
<ul>
<li>This city is the clear winner of Zillow's 2024 Home Value Forecast —<a href="https://www.benzinga.com/money/winner-zillow-2024-home-value-forecast"> No surprise as the number of millionaires there grew by 75% in the last decade.</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
</ul>
For the second consecutive year, Gahanna, Ohio, a suburb of Columbus, claimed the top spot as the most in-demand ZIP code in the U.S. The study, which analyzed 29,000 ZIP codes nationwide, based its rankings on the frequency of listing views and the speed at which homes sold.
According to the report, Gahanna&#8217;s appeal lies in its combination of spacious homes, relatively affordable prices, and proximity to a major city. With a median listing price of $345,000, compared to the national median of $439,950, Gahanna offers value for buyers seeking more space without breaking the bank.
Trending: A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a>
The study found a clear geographic trend, with all top 10 ZIP codes in the Midwest or Northeast. The shift reflects a cooling housing market in the South, partly due to increased inventory in that region.
Daniel Hale, chief economist at Realtor.com, said, &#8220;All of the top 10 ZIP codes offer affordability in the form of a lower median list price or median listing price per square foot compared to the U.S. housing market, relative to their surrounding metropolitan area, or both in June."&nbsp;
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
 She continued, "Though buyers have more options across the country, this year's Hottest ZIP Codes show that demand remains concentrated in markets that offer more bang for your buck.&#8221;
The list includes several commuter-friendly neighborhoods near major cities like New York and Boston. While some areas feature home prices above the national median, they offer relative affordability compared to properties closer to urban centers.
Trending: Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
For example, the median listing price of $995,000 in Basking Ridge, New Jersey, might seem steep. However, it represents a discount compared to nearby New York City, with homes offering about 33% more space per dollar than the surrounding metro area.
The study also highlighted the intense competition in the markets. Homes in the top 10 ZIP codes typically sold within 21 days, less than half the national median of 50 days. That rapid turnover drives up prices, with the hottest markets seeing an average 7.4% increase in median listing prices, compared to just 0.4% nationally.
See Also: This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a>
The report said buyers in those areas tend to be older and more financially secure than the national average. The typical successful buyer in those markets had a credit score of 757 and made a down payment of 16.7%, higher than national averages. The complete list of the top 10 hottest ZIP codes, as ranked by Realtor.com:
<ol>
<li>43230 – Gahanna, OH</li>
<li>63021 – Ballwin, MO</li>
<li>01970 – Salem, MA</li>
<li>07920 – Basking Ridge, NJ</li>
<li>14609 – Rochester, NY</li>
<li>08054 – Mount Laurel, NJ</li>
<li>01453 – Leominster, MA</li>
<li>01085 – Westfield, MA</li>
<li>46322 – Highland, IN</li>
<li>18062 – Macungie, PA</li>
</ol>
As the <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39614880/now-owning-a-house-in-us-is-more-challenging-than-ever-as-affordability-drops-to-">housing market continues </a>its rout, potential homebuyers who are seeking value might want to consider the above areas, which offer opportunity in a challenging market.
Read Next:
<ul>
<li>Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Investing in its booming real estate market has never been more accessible.</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

The 10 Most In-Demand ZIP Codes For Homebuyers – Is Your City On The List?

<ul>
<li>Once issued, this patent provides U.S. intellectual property coverage of UroGen's RTGel&#xAE; technology with medac lyophilized mitomycin formulation, covering UGN-103 and UGN-104 development programs until December 2041</li>
</ul>
UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/535,108 entitled "Material and Method for Treating Cancer."
The allowed claims relate to the combination of UroGen's RTGel&#xAE; technology with medac's licensed proprietary lyophilized mitomycin formulation and cover the use of UroGen's UGN-103 and UGN-104 development programs in the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) and low-grade upper tract urothelial cancer (LG-UTUC), respectively. The U.S. patent, once issued, will have an expiration date in December 2041.

URGN

UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041

WIIM

KRRO

Korro Bio shares are trading higher after the company announced a collaboration with Novo Nordisk to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases.

Following a comprehensive search by the Company's Board of Directors, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.latticesemi.com%2F&amp;esheet=54122233&amp;newsitemid=20240916026113&amp;lan=en-US&amp;anchor=Lattice+Semiconductor+Corporation&amp;index=1&amp;md5=9aef85056b37e4a05b64287903fef7de">Lattice Semiconductor Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) today announced the appointment of Dr. Ford Tamer as Chief Executive Officer and to the Company's Board of Directors, effective immediately.

Management

LSCC

Lattice Semiconductor Appoints Ford Tamer As CEO, Effective Immediately

Green Thumb Industries Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GTII#CSE">GTII</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>), the owner of RISE Dispensaries, announced a $50 million share repurchase program on Monday.
What Happened: The company's board of directors approved the repurchase of up to 10,573,860 of its subordinate voting shares from time to time over the next 12 months.
The program will commence on Sept. 23, 2024, and expire on Sept. 22, 2025. Green Thumb's previous repurchase program expired on Sept. 10, 2024, under which the company repurchased 6.5 million shares for $73.3 million.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16080441/ccc-oct-24-banner__1_-21.gif" alt="" class="wp-image-549412" /></a></figure>
The news comes on the heels of the company's announcement that it has closed on a $150 million five-year syndicated credit facility led by Valley National Bank, <a href="https://www.benzinga.com/markets/cannabis/24/09/40834346/cannabis-giant-green-thumb-secures-150m-credit-facility-strengthens-our-already-clean-balance-sh">the principal subsidiary of Valley National Bancorp.</a>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40175373/green-thumbs-q2-revenue-soars-11-to-280m-is-rising-cost-something-to-watch">Green Thumb's Q2 Revenue Soars 11% To $280M, Is Rising Cost Something To Watch?</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Why It Matters: Green Thumb CEO Ben Kovler said the buyback program allows it to be more flexible in using its cash reserves to repurchase more shares, if an opportunity arises.
"We love our balance sheet, particularly in light of the recent refinancing, and remain open to strategic M&amp;A, capital expenditures into the business and unique investment opportunities," Kovler said. "The future is bright for Green Thumb as America craves more well-being and more cannabis."
In June, Green Thumb expressed interest in merging with Boston Beer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>), a deal observers thought could reshape the <a href="https://www.benzinga.com/topic/cannabis-beverages">cannabis and beverage sectors</a>. The transaction would create a company with $3 billion in proforma 2023 revenues, with two-thirds from Boston Beer.
<h3 class="wp-block-heading">GTBIF Price Action</h3>
Green Thumb's shares traded 0.04% higher at $10.33 per share after the market close on Friday afternoon.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40427128/verano-green-thumb-marimeds-strong-q2-unpacking-the-cannabis-earnings-surge">Verano, Green Thumb &amp; MariMed's Strong Q2: Unpacking The Cannabis Earnings Surge</a></li>
</ul>

Cannabis

Financing

CSE:GTII

GTBIF

GTII

Cannabis Giant Green Thumb Confirms $50M Share Repurchase Program, CEO Open To M&A And 'Unique Investments'

EF Hutton analyst Jason Kolbert initiates coverage on Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy rating and announces Price Target of $17.

Price Target

Initiation

IMUX

EF Hutton Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $17

Sterling Bancorp shares are trading higher after the company announced the sale of Sterling Bank and Trust F.S.B. to EverBank Financial Corp. Also, the company adopted a plan of dissolution and expects to wind down as quickly as possible after the sale.

&nbsp;Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.
As previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Hospital has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022. Guangzhou Hospital has also subsequently submitted the application for the License for such proton equipment, planning to offer proton therapy treatment services at its proton center. On September 14, 2024, the National Health Commission of the PRC announced to grant approval to Guangzhou Hospital's application for the License. Guangzhou Hospital&nbsp;plans to start its proton therapy treatment services at its earliest convenience after necessary preparations.

Concord Medical Announces Obtaining Large Medical Equipment Procurement License For Its Proton Therapy Equipment

Cantor Fitzgerald analyst Louise Chen reiterates Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) with a Overweight.

EOLS

Cantor Fitzgerald Reiterates Overweight on Evolus

Theriva&#x2122; Biologics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NYSE">TOVX</a>), ("Theriva" or the "Company") a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the THERICEL project has been awarded funding of €2.28 million from the National Knowledge Transfer Program of the Spanish government's Ministry of Science, Innovation &amp; Universities to support a collaboration between the Company and the Universitat Autònoma de Barcelona (UAB) to advance the Company's suspension cell platform for the clinical manufacture of adenovirus- and adeno-associated virus (AAV) therapies. Under the award, Theriva will receive a loan of €1.33 million as a lump sum payment in Q4 2024 which shall be repaid over 7 years commencing three years from the date of award and UAB will receive a grant of €0.95 million dedicated to the THERICEL project and paid in annual installments over the next 3 years.

Contracts

TOVX

Theriva Biologics Announces That The THERICEL Project Has Been Awarded Funding Of €2.28 Million From The National Knowledge Transfer Program Of The Spanish Government's Ministry Of Science, Innovation & Universities To Support A Collaboration Between The Universitat Autònoma De Barcelona To Advance The Company's Suspension Cell Platform For The Clinical Manufacture Of Adenovirus- And Adeno-Associated Virus Therapies

Instill Bio shares are trading lower. The company announced  the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer and in front-line triple-negative breast cancer.

An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens &nbsp;
Underscores ozuriftamab vedotin's activity in a high unmet need SCCHN patient population
The conditionally binding ADC targeting ROR2 was notably well tolerated
The Company intends to meet with the FDA to discuss a SCCHN potential registrational trial in 2H 2024
SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today presented a poster of promising Phase 2 trial data at the European Society for Medical Oncology (ESMO) Annual Meeting. The poster presentation entitled, "Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck," reported multiple confirmed responses among heavily pretreated patients who tolerated treatment well. The Company's novel, conditionally active anti-ROR2-ADC was recently granted FDA Fast Track Designation for treatment of patients with recurrent or metastatic (R/M) SCCHN.

BCAB

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity With Manageable Tolerability Among Heavily Pretreated Patients With Squamous Cell Carcinoma Of The Head And Neck At The 2024 ESMO Annual Meeting

Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and maintains $170 price target.

ASND

Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $170 Price Target

The first big economy-focused poll conducted after the <a href="https://www.benzinga.com/news/24/09/40806876/final-showdown-trump-and-harris-face-off-in-intense-debate-just-eight-weeks-before-election-day">televised debate between Vice President Kamala Harris and her Republican rival Donald Trump </a>showed that the former may be solidifying her lead versus the latter.
The Matchup: Harris led Trump on stewardship of the economy with a 44%-42% tally, giving her a two-point lead, an FT-Michigan Ross poll <a href="https://www.ft.com/content/5f68cc51-f608-4fab-bfa3-8a9187236116">showed.</a> This is an improvement from last month&#8217;s survey, which produced a 42%-41% tally in favor of the vice president.
The poll was conducted online by Democratic strategists Global Strategy Group and Republican polling firm North Star Opinion Research from September 11-12. It surveyed 1,002 registered voters, with the margin of error at plus or minus 3.1 percentage points.
Debate watchers viewed her economic stewardship as better than those who didn&#8217;t, the poll found. The debate was watched by about 67 million Americans, FT said, citing Nielsen data. Nearly, 75% of respondents who watched the debate said they watched all or part of the 90-minute debate. 
See Also: <a href="https://www.benzinga.com/news/24/09/40867103/nate-silver-if-trump-loses-he-will-have-let-election-slip-out-of-his-grasp-as-underlying-factors-fav">Nate Silver: If Trump Loses, He Will Have Let Election &#8216;Slip Out Of His Grasp&#8217; As Underlying Factors Favor Him Despite Harris&#8217; Poll Lead</a>
Debate Redeems Harris: Forty-eight percent of debate watchers said they trusted Harris more to manage the economy, while slightly less than 42% said the same about Trump. On the contrary, among those who didn&#8217;t watch the debate, Trump had an edge (41%) over Harris (35%) regarding their credentials to steward the economy.
The poll also found that Harris was trusted significantly more than President Joe Biden on the economy. Biden never beat Trump on the question of who voters trusted more to manage the economy, and Harris's support, from 44% of Americans, is an eight-point improvement over Biden, the pollster said.
The numbers prove that Harris might be getting her messaging right and was succeeding in distancing from an &#8220;unpopular incumbent even without articulating a clear economic agenda that differs from Biden's,&#8221; FT said.
Harris led Trump by a margin of 44%-43% as someone who can be trusted to lower costs of every necessity like food and fuel. She is also viewed as more trusted to help the unemployed find a job, by a similarly tight 44% to 42%.
Harris is seen as better representing the interests of the middle class:
<ul>
<li>middle class (49%-36%)</li>
<li>small businesses (48%-37%)</li>
<li>union members (45%-35%)</li>
<li>blue-collar workers (43%-36%)</li>
</ul>
On the other hand, Trump was seen as better representing the interests of large corporations by a 64%-20% margin and the wealthy by a 67%-19% margin.
&#8220;Voters also think [Harris] represents ‘people just like them' better, and that is important given the tendency of people to vote for the candidate they think will do the most for them," said Erik Gordon, a professor at the University of Michigan's Ross School of Business. 
One Sore Point: Voters, however, believed they would be better off if Trump were re-elected as he led Harris by a 40%-35% margin on this count.
The poll is likely to be welcomed by the vice president's campaign, given &#8220;Harris and the Democrats have historically struggled to convince voters that they are better stewards of the economy than their Republican counterparts,&#8221; the report said.
The pushback against her is that is economy is not her forte. Former White House Communications Director Anthony Scaramucci, who was brought in as one of her surrogates during last week&#8217;s debate, said in a recent podcast that she has to get the message across that <a href="https://www.benzinga.com/news/24/09/40869771/anthony-scaramucci-explains-how-kamala-harris-can-improve-her-poor-economic-polling-she-has-to-get-o">she can lead Americans to a better economic future than Trump.</a>
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year.&nbsp;<a href="https://www.benzinga.com/gov-trades" target="_blank" rel="noreferrer noopener">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image via Kamala Harris

Politics

Media

Trump Vs. Harris: Vice President Widens Lead On Key Election Issue That Is Democrats' Achilles' Heel As Debate Performance Establishes Her As Better Economic Steward

<a href="https://www.globenewswire.com/Tracker?data=PI-gsuuCoJiDa6las5_tmKawCSZijCOBLDMuz35w6NzKVGfZpCfCB_z1dqMUnqwIF5fx80bq92rNrSo6UwRncROKnqFPfkaaCBAQDS7yLrw=">InnovAge Holding Corp.</a> ("InnovAge") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>), a leading Program of All-inclusive Care for the Elderly (PACE) provider, has been selected as a research partner for a national study exploring how to prevent falls by seniors. This September's National PACE Awareness Month and Falls Prevention Month observances emphasize the impact of this timely and critical work aimed at reducing dangerous falls by seniors, as well as helping many others facing a wide range of health conditions. &nbsp;
According to the <a href="https://www.globenewswire.com/Tracker?data=L84C43JsgiFCpaesnmoHjAjIquEtoPYUn1GbwUQyJO5vzbbrOuwlvuu-8EZ9FFMKybVxzlsGVGJDFO2Dbg5Idolo1BLSaMWFuLjZUiG6NLA=">CDC</a>, falls are the leading cause of injury and death among older adults, with one in four adults aged 65 and older experiencing a fall each year. InnovAge participants average 16% fewer falls than the National PACE Association's estimated average1 through proactive screening, risk assessments, and personalized interventions designed to prevent falls. As the largest PACE provider (of enrolled participants), InnovAge provides comprehensive emotional, physical, and social support to older adults through 24/7, integrated care.

INNV

InnovAge Selected To Participate In National Study Focused On Preventing Falls By Seniors

- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients &nbsp;
Boston (September 16, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that two patients enrolled in its Phase 2 clinical trial of stenoparib for advanced, recurrent ovarian cancer have now exceeded one year on therapy.
The patients had been pre-screened using Allarity's Drug Response Predictor (DRP&#xAE;) companion diagnostic, which identified them as having a high likelihood of benefiting from stenoparib, the Company's novel dual PARP/Tankyrase inhibitor.
This remarkably lengthy treatment period highlights the potential of stenoparib to provide durable clinical benefit, even in heavily pre-treated ovarian cancer patients who have limited treatment options. The trial continues to evaluate stenoparib's safety and efficacy, showing a confirmed, complete response as well as long term disease stability for multiple patients.

ALLR

Allarity Therapeutics Announces 2 Patients Now Exceeding 1-Year Of Treatment With Stenoparib In Advanced Ovarian Cancer Trial

Senior executives and board members of SRx Health have purchased 10,000 shares in the open market &nbsp;
Better Choice's share repurchase program has been activated and the Company has purchased shares amid the volatility
TAMPA, Fla., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#NYSE">BTTR</a>) ("Better Choice" or the "Company"), a pet health and wellness company, today announced that certain board members and senior management of SRx Health Solutions Inc. have purchased 10,000 shares of Better Choice common stock.
Additionally, Better Choice has activated its share repurchase program and has purchased shares in the open market.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

AmTrust Financial Servs

News

Latest news for AmTrust Financial Servs (OTC:AFSIB) Stock